• 1
    Sanchez CJ, Le Treut T, Boehrer A, Knoblauch B, Imbert J, Olive D, Costello R. Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity. Cancer Immunol Immunother 2011; 60:113.
  • 2
    Carbone E, Neri P, Mesuraca M et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005; 105:2518.
  • 3
    Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, Gregory SA. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia 2008; 22:9981006.
  • 4
    von Lilienfeld-Toal M, Frank S, Leyendecker C et al. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. Cancer Immunol Immunother 2010; 59:82939.
  • 5
    Fauriat C, Mallet F, Olive D, Costello RT. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia 2006; 20:7323.
  • 6
    Hosen N, Ichihara H, Mugitani A et al. CD48 as a novel molecular target for antibody therapy in multiple myeloma. Br J Haematol 2012; 156:21324.
  • 7
    Greipp PR, San MJ, Durie BG et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23:341220.
  • 8
    Kyle RA, Durie BG, Rajkumar SV et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24:11217.
  • 9
    Eissens DN, Spanholtz J, van der Meer A, van Cranenbroek B, Dolstra H, Kwekkeboom J, Preijers FW, Joosten I. Defining early human NK cell developmental stages in primary and secondary lymphoid tissues. PLoS ONE 2012; 7:e30930.